FGF4, fibroblast growth factor 4, 2249

N. diseases: 86; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 GenomicAlterations disease CGI
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 GeneticVariation disease BEFREE (2) The human homolog of int-2, located on chromosome 11q13, is frequently amplified in human primary tumors and is comprised in an amplification unit encompassing the hst gene, which is often coamplified; the amplification at the 11q13 locus in breast carcinomas correlates with a poor outcome of the disease. 2677918 1989
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Although evaluation of the clinical significance of HST amplification and expression must await long-term follow-up of the patients, we suggest that HST gene product could play a role in development and/or progression of human breast cancer. 2474139 1989
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE In an attempt to probe the significance of HST and INT-2 gene amplification in human breast carcinomas, we have surveyed the amplification status of five molecular markers located on the long arm of chromosome 11 (BCL-1, HST, INT-2 & SEA on 11q13, and ETS-1 on 11q23) in a population of 297 mammary tumors. 2181375 1990
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE The glutathione S-transferase gene (GST pi) is located on the same chromosome band (11q13) as proto-oncogenes INT2 and HSTF1 which are frequently amplified in breast cancer. 1826346 1991
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE BCL1 and two proto-oncogenes, INT2 and HST, were previously found to be coamplified in approximately 1/5 breast carcinomas. 2071147 1991
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. 8481921 1993
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 AlteredExpression disease BEFREE Mechanisms, including ras activation, fibroblast growth factor 4 expression, and human DNA methyltransferase activation causing ER promoter methylation, which are respectively known to induce estrogen-independent growth, induce spontaneous metastasis, and decrease ER levels in breast carcinoma experimentally, were not mechanisms operating in the hybrids. 8758927 1996
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 AlteredExpression disease BEFREE Other members of the fibroblast growth factor family have been either not expressed in the human breast (FGF3, FGF4) or have been found at much reduced levels in breast cancer (FGF1, FGF2) and this is the first member of the family to potentially influence the progression of breast cancer through stimulation of cell division. 9184170 1997
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE The CCND1-FGF19-FGF4-FGF3 gene cluster in human chromosome 11q13 is amplified in breast cancer, squamous cell carcinoma of head and neck, and bladder tumors, and is also translocated in parathyroid tumors and B-cell lymphoma. 12429977 2002
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 AlteredExpression disease BEFREE Furthermore, overexpressing OCT3 stimulated endogenous FGF-4 expression in MCF7 breast cancer cell line. 12841847 2003
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Because HST is described as an endogenous pan-HER inhibitor, the presence of this protein in breast carcinomas may portent the inefficiency of exogenous efforts to block HER2 dimerization, whereas its absence may justify such interventions. 18592003 2008
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease CTD_human Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. 21936542 2011